- Previous Close
0.5583 - Open
0.5287 - Bid 0.5408 x 100
- Ask 0.5956 x 100
- Day's Range
0.4720 - 0.8600 - 52 Week Range
0.4720 - 4.8000 - Volume
836,299 - Avg. Volume
532,471 - Market Cap (intraday)
3.294M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a containment barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
www.polyrizon-biotech.comRecent News: PLRZ
View More
Performance Overview: PLRZ
Trailing total returns as of 3/24/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PLRZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PLRZ
View MoreValuation Measures
Market Cap
3.29M
Enterprise Value
3.88M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.62
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.65%
Return on Equity (ttm)
-57.83%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.6M
Diluted EPS (ttm)
-0.5000
Balance Sheet and Cash Flow
Total Cash (mrq)
2.55M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-771.75k
Company Insights: PLRZ
PLRZ does not have Company Insights